Rotigotine
RxNorm 616739
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 616739 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Rotigotine.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
FNPrescribable
Full form of descriptor (FN):
Product containing rotigotine (medicinal product)
(Atom ID: 9731436)
INPrescribable
Ingredient (IN):
Rotigotine
(Atom ID: 12251778)
PTPrescribable
Designated preferred name (PT):
Rotigotine
(Atom ID: 2546895)
FNPrescribable
Full form of descriptor (FN):
Rotigotine (substance)
(Atom ID: 2546897)
PTPrescribable
Designated preferred name (PT):
Rotigotine-containing product
(Atom ID: 10820446)
Patient Education
Rotigotine Transdermal Patch
Rotigotine transdermal patches are used to treat the signs and symptoms of Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance) including shaking of parts of the body, stiffness, slowed movements, and problems with balance. Rotigotine transdermal patches are also used to treat restless legs syndrome (RLS or Ekbom syndrome; a condition that causes discomfort in the legs and a strong urge to move the legs, especially at night and when sitting or lying down). Rotigotine is in a class of medications called dopamine agonists. It works by acting in place of dopamine, a natural substance produced in the brain that is needed to control movement.
[Learn More]
* Please review the disclaimer below.